Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Instagram Outage Disrupts Thousands of U.S. Users 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
STAMFORD, Conn., Aug. 01, 2017 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for the second quarter ended June 30, 2017 on August 8, 2017 before the NASDAQ market open.
The company will not be conducting a conference call in conjunction with this earnings release.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
[email protected]
Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
[email protected]
Media:
Dan Budwick
1AB Media
973-271-6085
[email protected]
